Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in anuric haemodialysis patients with end-stage kidney disease
ACTRN12623001237673Phase 3Not yet recruiting
- Sponsor
- Dobney Hypertension Centre
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in end-stage kidney disease (ESKD), sponsored by Dobney Hypertension Centre. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12623001237673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001237673.